TVD-101-003P; TTI-101 for IPF

Internal Medicine Pulmonology Lung Disease Adult Subjects

The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).

MKC-CI-002, MNKD-101, Pulmonary Nontuberculous

Internal Medicine Pulmonology Lung Disease Adult Subjects

This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)

CAIN457E22101; IV secukinumab for GCA or PMR

Internal Medicine Infectious Disease Pulmonology Bacterial Infectious Diseases Lung Disease Adult Subjects

This study will examine how intravenous (i.v.) Secukinumab will be processed in the body (pharmacokinetics \[PK\]) and whether it will be safe and tolerable after multiple doses of i.v. Secukinumab infusion in adult patients with giant cell arteritis (GCA) or polymyalgia rheumatica (PMR).

XeLHC

Radiology Pulmonology Lung Disease Adult Subjects

A subset of young adults participating in the American Lung Association (ALA) Lung Health Cohort (LHC) will be imaged using Hyperpolarized 129Xe MRI to assess lung structure and function. Images will be used to improve the understanding of lung health and early lung abnormalities that may lead to chronic lung disease.

XTMAB-16-202, XTMAB-16 for Pulmonary Sarcoidosis

Internal Medicine Pulmonology Lung Disease Adult Subjects

Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra-pulmonary Involvement

IM0271015 BMS-986278 for Progressive Pulm Fibrosis

Internal Medicine Pulmonology Lung Disease Adult Subjects

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

AV001-004, AV-001 for Pneumonia

Internal Medicine Infectious Disease Pulmonology Heart and Vascular COVID-19 Influenza Respiratory Distress Syndrome Bacterial Infectious Diseases Lung Disease Infectious Disease Vascular Disease Adult Subjects

A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen therapy. The purpose of this study is to examine the safety, tolerability and efficacy of AV-001 Injection administration daily to the earlier of day 28 or EOT (day prior to hospital discharge). A total of 120 eligible patients (20 patients in each of cohort 1, 2 and 3 and 60 patients in cohort 4) will be recruited from up to 25 participating institutions/hospitals. Patients will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC).

IM027068 BMS-986278 for Idiopathic Lung Fibrosis

Internal Medicine Pulmonology Lung Disease Adult Subjects

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.